Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer-Reference-Cited by-同舟云学术

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer

Published:2018-09-20 Issue:1 Volume:35 Page:73-80
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Princic Nicole¹,Aizer Ayal²,Tang Derek H.³,Smith David M.¹,Johnson William¹,Bardia Aditya⁴

Affiliation:

1. IBM Watson Health, Cambridge, MA, USA;

2. Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, MA, USA;

3. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

4. Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1519500

Reference21 articles.

1. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

2. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality

3. Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer

4. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study;Cancers;2024-08-20

2. Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer;Journal of Oncology Pharmacy Practice;2024-02-25

3. Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data;International Journal of Molecular Sciences;2023-09-22

4. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review;Targeted Oncology;2023-04-19

5. Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer;Cancers;2023-03-28